Litigation Details for Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited (D. Del. 2019)
✉ Email this page to a colleague
Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited (D. Del. 2019)
| Docket | ⤷ Subscribe | Date Filed | 2019-10-24 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | Assigned To | Leonard Philip Stark | |
| Jury Demand | Referred To | ||
| Patents | 8,101,659; 8,796,331; 8,877,938; 9,388,134 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited
The small molecule drugs covered by the patents cited in this case are ⤷ Subscribe and ⤷ Subscribe .
Details for Novartis Pharmaceuticals Corporation v. Alembic Pharmaceuticals Limited (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-01-06 | 14 | Answer to Complaint | United States Patent Nos. 8,101,659 (the “’659 patent”), 8,796,331 (the “’331 patent”), and 8,877,938…103 mg, prior to the expiration of U.S. Patents Nos. 8,101,659 (the Case 1:19-cv-02021-LPS Document…and every asserted claim of United States Patent No. 8,101,659 is invalid for failing to satisfy one or… and enforceable asserted claim of U.S. Patent No. 8,101,659. …entered that each claim of United States Patent Nos. 8,101,659, 8,796,331, and 8,877,938 is invalid; | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
